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The discovery that a number of metabolites and metabolic intermediates can act through
G protein-coupled receptors has attracted great interest in the ﬁeld and has led to new
therapeutic targets for diseases such as hypertension, type 2 diabetes, inﬂammation, and
metabolic syndrome. However, the low apparent afﬁnity of these ligands for their cognate
receptors poses a number of challenges for pharmacologists interested in investigating
receptor structure, function or physiology. Furthermore, the endogenous ligands matched
to their receptors have other, well established metabolic roles and thus selectivity is difﬁ-
cult to achieve. This review discusses some of the issues researchers face when working
with these receptors and highlights the ways in which a number of these obstacles have
been overcome.
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Gprotein-coupled receptors (GPCRs) respond to a diverse array of
stimuli,making them obvious targets for therapeutic exploitation.
Indeed, ligands for GPCRs currently account for ∼30% of FDA-
approved pharmaceuticals (Overington et al., 2006). Despite great
progress, few GPCRs are targeted therapeutically and more than
80 non-olfactory GPCRs remain to be deorphanized (matched
to their cognate endogenous ligand; Allen and Roth, 2011). Ini-
tial deorphanization approaches involved screening a small group
of known transmitters against a larger group of cloned receptors
(Civelli, 2005). However, as the number of un-partnered transmit-
ters dwindled, the concept of “reverse pharmacology” was born,
where a known GPCR of therapeutic interest (most likely due
to similarity to an existing therapeutically relevant GPCR or due
to a distinct tissue expression pattern) is screened against larger
libraries of potential endogenous mediators (Civelli, 2005). The
reverse pharmacology approach yielded a number of additional
ligand:receptor pairs, although some were found to come from
unusual sources, such as metabolic intermediates (Table 1). In
this review,“metabolic intermediate” refers to both true metabolic
intermediates which have been assigned no biological effect other
than comprising part of an essential metabolic pathway (e.g., suc-
cinate and β-hydroxybutyrate) and also to metabolites that are
produced from digestion and until recently were thought to medi-
ate their effects exclusively within the cell (e.g., free fatty acids,
FFAs). The GPCRs discussed herein are also notable in that their
apparent endogenous ligands interact at the receptors with low
afﬁnity.Whilst broadening the therapeutic options for a variety of
diseases, such as diabetes andmetabolic syndrome, these low afﬁn-
ity receptors have generated a number of additional challenges,
discussed below.
TARGET SPECIFICITY/SELECTIVITY
Target speciﬁcity or selectivity, the narrowness of the range of
targets in an organism, is by deﬁnition a challenge at metabolic
intermediate receptors. For example, succinate is a well established
intermediate in the tricarboxylic acid/citric acid cycle (Krebs,
1970), while long chain fatty acids have for years been consid-
ered as nutrients (Yaney and Corkey, 2003) rather than cell surface
ligands. Thus, distinguishing between GPCR-speciﬁc and non-
GPCR functions for these endogenous ligands can be particularly
challenging.
Coupled to the issue of lack of speciﬁcity is the apparent low
afﬁnity of the endogenous ligand:GPCR pairings. This has led
many to question whether certain ligands are correctly assigned as
the endogenous partner to the previously orphan receptor (Mil-
ligan et al., 2009; Milligan, 2011). Indeed, how can we determine
whether ligand:receptor pairings are correct? A number of criteria
must be met before a receptor is ofﬁcially deorphanized by the
International Union of Basic and Clinical Pharmacology Nomen-
clature Committee (NC-IUPHAR), including reproducibility of
the original observation, consistent ligand and receptor phar-
macology (often conﬁrmed by transgenic mouse models) and,
particularly pertinent to low afﬁnity GPCRs, that the tissue con-
centrations achieved by each ligand are compatible with activating
the cognate receptor (Sharman et al., 2011). This last point is
often the most contentious. For example, all three FFA receptors
are expressed in tissues where the local concentration of ligands
are accepted to reach concentrations required for receptor activa-
tion, such as after a meal (Stoddart et al., 2008b; Hudson et al.,
2011). In contrast, based upon reported potency values for succi-
nate in vitro (He et al., 2004), the SUCNR1 receptor is unlikely to
be activated except in cases where energy homeostasis has become
dysregulated, such as in diabetes or metabolic syndrome (Deen
and Robben, 2011), leading to it being viewed as a local sensor of
metabolic and oxidative stress (see Ariza et al., 2012). Similarly,
the lactate hydroxyl–carboxylic acid (HCA) receptor HCA1 (pre-
viously known as GPR81) is most likely activated after exercise or
hyperglycemia as this is when lactate plasma concentrations are
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Table 1 | Low affinity GPCRs for metabolites and metabolic intermediates.
Receptor name Previous name Ligand Ratified by IUPHAR? Ligand source
FFA1 GPR40 Medium and long chain free fatty acids Yes Food; fatty acid metabolism; β-oxidation
FFA2 GPR43 Short chain free fatty acids Yes Breakdown of ﬁber
FFA3 GPR41 Short chain free fatty acids Yes Breakdown of ﬁber
GPR35 Kynurenic acid (lysophosphatidic acid) No Tryptophan metabolism
HCA1 GPR81 Lactate Yes Glycolysis
HCA2 GPR109A β-Hydroxybutyrate Yes HMG-CoA ketogenesis pathway
HCA3 GPR109B 3-Hydroxy-octanoic acid Yes β-Oxidation
GPR120 Long chain free fatty acids No Food; fatty acid metabolism; β-oxidation
GPBA TGR5 Bile acids Yes Cholesterol metabolism
SUCNR1 GPR91 Succinate No Citric acid cycle
commensurate with activation (Ahmed et al., 2010). In contrast,
kynurenic acid (KYNA)has been questioned asGPR35’s legitimate
ligand as a result of failing the above criteria. AlthoughKYNA ago-
nism has been repeated by others, receptor activation occurs with
micromolar potency (Jenkins et al., 2010, 2011; Zhao et al., 2010)
while endogenous plasma concentrations of KYNA remain in the
nanomolar range (see MacKenzie et al., 2011). The vast discrep-
ancy in agonism at rodent versus human GPR35 (see below) is
another concern, as is the discovery that lysophosphatidic acid can
equally activate the receptor (Oka et al., 2010). NC-IUPHAR has
recently released a statement indicating their reasons for not yet
ratifying KYNA as the ligand for GPR351. For researchers new to
the ﬁeld, the NC-IUPHAR is a useful starting point for under-
standing legitimate versus spurious ﬁndings at GPCRs as their
database is curated by a panel of esteemed pharmacologists (Foord
et al., 2005).
Discrimination between speciﬁc effects of the metabolic inter-
mediates at GPCRs versus their other physiological roles (here
considered to be off-target effects) is hampered by a number of
confounding issues. First, a number of the targets have overlap-
ping tissue distributions. For example, the LCFA FFA1 receptor
is found in the pancreas and is a promising target for the treat-
ment of type 2 diabetes (Swaminath, 2008; Alquier and Poitout,
2009; Kebede et al., 2009; Hara et al., 2011). Although its predom-
inant site of action as an insulin sensitizer is at adipose tissue,
the widely expressed peroxisome proliferator-activated receptor,
PPARγ, which also responds to LCFAs, is similarly expressed in the
pancreas (Michalik et al., 2006). Furthermore, a selection of the
insulin-sensitizing thiazolidinedione PPARγ agonists also activate
FFA1 (Kotarsky et al., 2003; Smith et al., 2009), indicating sim-
ilarity of both expression patterns and ligand pharmacophores.
FFA1 expression patterns also overlap with that of another LCFA
GPCR, GPR120, in taste buds (Matsumura et al., 2007; Cartoni
et al., 2010), and enteroendocrine cells (Edfalk et al., 2008; Liou
et al., 2011). In another example, the overlap of expression pat-
terns is a source of debate. FFA3 has alternately been reported
as having adipose tissue expression (Brown et al., 2003; Xiong
et al., 2004) or lacking it (Hong et al., 2005; Zaibi et al., 2010),
1http://www.iuphar-db.org/latestPairings.jsp
with mounting evidence pointing toward an FFA2-, not FFA3-,
mediated role for adipocyte short chain FFAs (SCFAs; Hong et al.,
2005; Ge et al., 2008; Zaibi et al., 2010; Dewulf et al., 2011). Sec-
ond, some low afﬁnity GPCRs are co-expressed and mediate the
samephysiological pathways as their non-GPCRcounterparts. Bile
acids, for example, activate both the GPCR, GPBA (also known as
TGR5), and the nuclear hormone receptor, farnesoid X receptor
(FXR), both of which are highly expressed in the liver and intes-
tine where they play complementary roles in bile acid homeostasis
and signaling (Chen et al., 2011). Third, both FFA2 and FFA3
receptors display overlapping tissue expression, respond to the
same SCFAs and couple to Gαi/o signaling pathways (Brown et al.,
2003; Stoddart et al., 2008b; Milligan et al., 2009), indicating that
true physiological characterization requires knockout mice or the
development of selective ligands.
As pharmacologists, how can we discriminate between GPCR
and off-target effects of these low afﬁnitymetabolic intermediates?
For SCFA receptors, there are subtle differences in the rank order of
potency between FFA2 and FFA3 (Brown et al., 2003; Le Poul et al.,
2003; Schmidt et al., 2011), allowing for subtype distinction based
upon pharmacological parameters. Likewise, primary and sec-
ondary bile acids display different rankorders of potency forGPBA
and FXR (Maruyama et al., 2002; Kawamata et al., 2003). Signal-
ing outcomes are another way of discriminating between speciﬁc
and non-speciﬁc effects. Although FFA2 and FFA3 both couple
to Gαi/o, FFA2 additionally couples to Gαq/11, so inositol phos-
phates generation by SCFAs should be speciﬁc to FFA2 (Brown
et al., 2003; Le Poul et al., 2003). Similarly, although FFA1 and
GPR120 are both activated by LCFAs and signal through Gαq/11,
only GPR120 robustly recruits β-arrestins in in vitro transloca-
tion assays (see Holliday et al., 2012). The time-course of signaling
can also assist with discriminating between GPCR and non-GPCR
functions, as nuclear receptors such as PPARγ and FXR result
in transcriptional activation/repression (a process which takes
hours) whilst FFA1 and GPBA activate second messengers within
seconds/minutes.
Although an effective way to discriminate between targets, the
abovementioned distinctions are cumbersome at the experimental
level. More practical approaches rely upon the removal or absence
of the off-target effector, either pharmacologically or genetically. A
commonly used method is heterologous expression of the GPCR
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of interest in a cell line lacking each target or the identiﬁcationof an
endogenous cell line expressing only one of the targets. Arguably
the most successfully applied expression system is the inducible
FlpIN TRex method from Invitrogen2 where the gene of inter-
est is stably integrated into the same genomic site of a polyclonal
pool of cells and receptor expression is induced by the addition
of tetracycline (Ward et al., 2011). Because of the likelihood of
off-target effects being present at the high concentrations required
to activate the metabolic intermediate receptors, each experiment
can be performed in parallel in cells lacking the induced receptor.
This method has been used to investigate the pharmacology of
FFA1 (Stoddart et al., 2007; Smith et al., 2009), FFA2 and FFA3
(Schmidt et al., 2011; Smith et al., 2011b), GPR35 (Jenkins et al.,
2010, 2011), and SUCNR1 (Robben et al., 2009). An alternative to
parallel experimentation is the use of antagonists to the off-target
protein. For example, the rapid and transient effects of LCFAs and
thiazolidinediones on ERK1/2 activation were demonstrated to
occur through FFA1 and not PPARγ by the use of various PPARγ
and FFA1 antagonists (Smith et al., 2009). Unfortunately such
selective ligands are not always available.
Despite the precautions being taken by pharmacologists to
establish selectivity/speciﬁcity of each of the endogenous lig-
and:receptor interactions, new challenges continue to arise. For
example, a very recent study demonstrated that while FFA3
responded to SCFAs to induce sympathetic outﬂow after a meal,
this receptor was antagonized by the ketone β-hydroxybutyrate,
thought to be the HCA2 endogenous agonist (Taggart et al.,
2005), in times of starvation or in diabetes (Kimura et al., 2011).
In another case, the apparent constitutive activity of FFA1 in
[35S]GTPγS activation assays was demonstrated to actually result
from ligand-mediated receptor activation due to endogenous ago-
nists released duringmembrane preparation (Stoddart et al., 2007;
Stoddart and Milligan, 2010). It seems likely that further unex-
pected interactions at these receptors will be discovered in the
future.
DETERMINATION OF LIGAND AFFINITY AND RECEPTOR
BINDING SITES
Traditionally, receptor afﬁnity has been determined by radiolabel-
ing high afﬁnity ligands (preferably antagonists) and subsequent
saturation and competition binding assays (Bylund and Toews,
1993; Keen, 1995; Bylund et al., 2004). These experiments yield
a plethora of information, including receptor expression levels,
afﬁnity of both the radiolabeled ligand and competingnon-labeled
ligands and association and dissociation kinetics. However, meta-
bolic intermediates are largely unsuitable for development as radi-
oligands, not least because of their low afﬁnity, but also because
of their numerous targets within the cell and, in some cases, their
capacity to integrate into the plasma membrane. The exception
to this is [3H]-nicotinic acid which has been used as a radiola-
bel at the HCA2 receptor since its discovery (Wise et al., 2003;
Offermanns et al., 2011). Thus, in the absence of high afﬁnity
small molecules amenable to radiolabeling, novel approaches are
required to demonstrate ligand binding and afﬁnity.
2www.lifetechnologies.com
While some radioligands have recently been reported in the
patent literature for metabolic intermediate GPCRs, including
FFA1 (Amgen,USpatent 2010/0298367A1) andFFA2 (Euroscreen,
WO2011092284A1), several groups have turned to alternative
methods for determining ligand afﬁnity. At FFA1, for example,
Hara et al. (2009) employed a ﬂow cytometry-based binding assay
to measure BODIPY-C12 binding to immunoprecipitated FFA1
receptors. A more radical approach came from Bartoschek et al.
(2010) who measured ligand binding of unlabeled FFA1 ago-
nists using saturation transfer difference 1H NMR spectroscopy.
Although informative these studies both had limitations, such as
the potential loss of afﬁnity by incorporation of the BOPIDY tag
into the ligand and the limited chemical diversity permitted for
the spectroscopy approach.
To circumvent the lack of radioligand binding assays, indirect
measures of receptor function have been employed to obtain esti-
mates of afﬁnity. Based upon the assumption that signals most
proximal to ligand binding and receptor activation are subjected
to the least ampliﬁcation, and therefore represent a 1:1:1 ratio of
ligand:receptor:readout, potency values are increasingly used as
proxy measures of afﬁnity. One common assay employed for this
purpose is the [35S]GTPγS activation assay, either using endoge-
nous or co-transfectedG proteins and rapid ﬁltration or immuno-
capture (Labrecque et al., 2009; Strange, 2010), or a receptor-G
protein fusion construct, which forces a strict 1:1 ratio (Milli-
gan, 2000; Milligan et al., 2004). These assays have been used
extensively for the metabolic intermediate GPCRs (for example,
Stoddart et al., 2007, 2008a; Smith et al., 2009, 2011b) but do
generally rely upon knowledge of the preferred G protein partner
(this can be overcome in some cases using the receptor-G protein
fusions). Another approach that avoids the problem of deciding
which G protein subunit to assay is that of β-arrestin recruitment
assays (Kocan and Pﬂeger, 2011). In assays where β-arrestin is
recruited to an occupied receptor and the signal readout is unam-
pliﬁed [e.g., bioluminescence resonance energy transfer (BRET)
and high content imaging of β-arrestin–GFP translocation] the
measured potency should be equivalent to the afﬁnity of the ligand
for the receptor. Of course, these approaches are not guaranteed to
work as not all GPCRs recruit β-arrestins (Liu et al., 2009, see Hol-
liday et al., 2012). Finally, to measure antagonist afﬁnity, any assay
that allows generation of consecutive agonist curves in the pres-
ence of various concentrations of antagonist, such that a Schild
plot or global analysis can be performed (Hall and Langmead,
2010), should yield afﬁnity estimates of the antagonist. However,
the low afﬁnity of the metabolic intermediate GPCRs can pro-
hibit the resolution of complete concentration–response curves at
sufﬁcient intervals.
In the absence of radioligands, how have the binding pock-
ets of these GPCRs been investigated? For a number of receptors,
sequence conservation and knowledge of the chemical structure
of the ligand enabled mapping of the binding pocket. All three
HCA receptors, for example, require a conserved arginine residue
in transmembrane helix 3 (TM3) for receptor activation (Tunaru
et al., 2005; Liu et al., 2009), presumably because the positive
charge of the amino acid interacts with the negative charge of the
carboxylic acid. This same residue (Arg3.36 according to the num-
bering of Ballesteros and Weinstein, 1995) was later shown to be
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critical for both KYNA and zaprinast activity at GPR35 (Jenkins
et al., 2011). Similar observations were made for the FFA fam-
ily, where Arg5.39 and Arg7.35 were absolutely required for FFA1
(Sum et al., 2007; Tikhonova et al., 2007; Smith et al., 2009), FFA2
(Stoddart et al., 2008a; Schmidt et al., 2011; Smith et al., 2011b),
and FFA3 (Stoddart et al., 2008a; Schmidt et al., 2011) activation.
Although none of these studies were able to directly demonstrate
loss of binding rather than a global perturbation of receptor acti-
vation, molecular modeling (Sum et al., 2007; Tikhonova et al.,
2007; Stoddart et al., 2008a; Schmidt et al., 2011) placed the lig-
ands and residues within the generally conserved GPCR binding
pocket. Additional evidence was also provided by the fact that an
allosteric agonist for FFA2, 4-CMTB (Lee et al., 2008), retained the
ability to activate the receptor at both single and double Arg5.39
and Arg7.35 mutant constructs (Smith et al., 2011b; Swaminath
et al., 2011), demonstrating that the receptors themselves were cor-
rectly folded and still responsive to activation. Using their model,
Tikhonova et al. (2008) developed and reﬁned a pharmacophore
model such that novel ligands could be screened in silico, leading
to the identiﬁcation of 15 new compounds active at FFA1. For
GPR120, in silico library screening was possible in the absence of
existingmutational data and although themodel wasn’t conﬁrmed
by mutagenesis, the discovery of novel GPR120 agonists suggests
the pharmacophorewas correct (Sun et al., 2010). Thus,despite the
obvious difﬁculties faced when working with low afﬁnity GPCRs,
signiﬁcant inroads can still be achieved.
SPECIES DIFFERENCES
A ﬁnal cautionary note is provided by studies using species
orthologs of the metabolic intermediate receptors. Traditional
drug discovery pipelines involve original hit discovery, often at
human receptors, followed by in vitro characterization and then
rodent models both to conﬁrm efﬁcacy in various disease states
and to determine ligand pharmacokinetics/pharmacodynamics.
Such a pipeline relies upon the assumption that each species
ortholog displays similar pharmacology to the human receptor.
This is not necessarily the case. A prime example is GPR35,
which displays markedly lower potency for zaprinast and KYNA
at human when compared to rat GPR35. This presents the very
real possibility that lead compounds with efﬁcacy in mice or rats
could fail once introduced into humans (for a nice review of this
issue, refer to Milligan, 2011). Fortunately, subsequent screening
campaigns have identiﬁed ligands with either human selectivity
(Jenkins et al., 2010; Zhao et al., 2010) or equivalent selectivity at
both human and rat GPR35 (Jenkins et al., 2010). Such a phenom-
enon at species orthologs is not limited to GPR35 – mouse FFA1
has been shown to respond to both SCFAs andmedium chain fatty
acids when expressed heterologously in Xenopus oocytes, in addi-
tion to the LCFAs that are characteristic agonists for human FFA1
(Stewart et al., 2006).
CONCLUDING REMARKS
There is a growing appreciation that orphan and poorly charac-
terized deorphanized GPCRs provide a largely untapped source
of new therapeutic targets. However, the metabolic intermediate
GPCRs provide a number of additional challenges to pharmacol-
ogists beyond those faced for high afﬁnity GPCRs. However, after
issues of low afﬁnity, lack of speciﬁcity/selectivity and the need to
use indirect measures of ligand binding have been considered, a
great deal of progress has been made in our understanding of the
physiological signiﬁcance of these receptors. Subtype selectivity
will remain a challenge to the ﬁeld and the use of bitopic ligands or
allosteric agonists/inhibitors (Smith et al., 2011a) may provide an
alternative to pharmacological targeting of the orthosteric binding
site in the future.
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